Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Study identifier:NIS-GRU-NEX-2009/2

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Medical condition

Upper gastrointestinal bleeding

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

300

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Jun 2010

Primary Completion Date: 01 Jun 2011

Study Completion Date: 01 Jun 2011

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Moscow, Russian Federation

Arms	Assigned Interventions
1 Patients with acute upper gastrointestinal bleeding	-

"There is no result for the study"

Documents available

CSR-NIS-GRU-NEX-2009-2
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Russia Clinical Study Information

+74957995699

elena.dublina@astrazeneca.com

Investigators

Principal Investigator

Boris R Gelfand, Prof

Department of the Russian State Medical University

Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Documents available

CSR-NIS-GRU-NEX-2009-2

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator